Fluconazole

Generic Name
Fluconazole
Brand Names
Diflucan
Drug Type
Small Molecule
Chemical Formula
C13H12F2N6O
CAS Number
86386-73-4
Unique Ingredient Identifier
8VZV102JFY
Background

Fluconazole, commonly known as Diflucan, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an azole antifungal, in the same drug family as ketoconazole and itraconazole. Fluconazole has many advantages over the other antifungal dr...

Indication

Fluconazole can be administered in the treatment of the following fungal infections:

1) Vaginal yeast infections caused by Candida

2) Systemic Candida infections

3) Both esophageal and oropharyngeal candidiasis

4) Cryptococcal meningitis

5) UTI (urinary tract infection) by Candida

6) Peritonitis (inflammation of the peritoneum) caused by Candida
...

Associated Conditions
Candida intertrigo, Candida pneumonia, Candida urinary tract infection, Candidemia, Candidiasis, Coccidioidomycosis, Esophageal Candidiasis, Fungal Infections, Fungal peritonitis caused by Candida, Meningitis, Cryptococcal, Oropharyngeal Candidiasis, Peritoneal candidiasis, Pneumonia cryptococcal, Pruritus, Skin Irritation, Systemic Candida Infections caused by Candida, Vaginal Candidiasis, Disseminated Candidiasis
Associated Therapies
-
Clinical Trials
Related News

Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis

Phase 3
Completed
Conditions
Candidemia
Interventions
Drug: Anidulafungin
Drug: Fluconazole
First Posted Date
2008-09-29
Last Posted Date
2019-04-04
Lead Sponsor
Pfizer
Target Recruit Count
70
Registration Number
NCT00761267
Locations
🇧🇷

Hospital Pequeno Principe, Curitiba, PR, Brazil

🇰🇷

Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of

🇺🇸

University of California - Los Angeles - Ronald Reagan UCLA Medical Center, Los Angeles, California, United States

and more 41 locations

Fluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams Birthweight

Phase 3
Completed
Conditions
Candidiasis
Interventions
Drug: placebo
Drug: fluconazole
First Posted Date
2008-08-14
Last Posted Date
2019-03-01
Lead Sponsor
Daniel Benjamin
Target Recruit Count
362
Registration Number
NCT00734539
Locations
🇺🇸

University of California-San Diego, San Diego, California, United States

🇺🇸

Riley Hospital, Indianapolis, Indiana, United States

🇺🇸

West Jersey Hospital - Voorhees, Voorhees, New Jersey, United States

and more 30 locations

Outcomes of Patients Who Fail to Respond to Fluconazole Treatment of Severe Candida Albicans Infections

Completed
Conditions
Fungal Infection by Site
Interventions
Drug: Fluconazole
First Posted Date
2008-07-24
Last Posted Date
2014-07-23
Lead Sponsor
CPL Associates
Target Recruit Count
28
Registration Number
NCT00721487
Locations
🇺🇸

CPL Associates,LLC, Buffalo, New York, United States

Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study

First Posted Date
2008-06-03
Last Posted Date
2011-05-30
Lead Sponsor
Pfizer
Target Recruit Count
216
Registration Number
NCT00689338
Locations
🇬🇧

Pfizer Investigational Site, London, United Kingdom

Comparative Trial of Micafungin Versus Fluconazole for Treating Esophageal Candidiasis

Phase 3
Completed
Conditions
Candidiasis, Oral
Interventions
Drug: Fluconazole
Drug: Micafungin
First Posted Date
2008-04-24
Last Posted Date
2014-09-18
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
523
Registration Number
NCT00666185
Locations
🇿🇦

2 Sites, Port Elizabeth, South Africa

🇵🇪

4 Sites, Lima, Peru

🇧🇷

8 Sites, Sao Paulo, Brazil

and more 2 locations

A Study Of Diflucan In Children With Ringworm Of The Scalp

Phase 3
Completed
Conditions
Tinea Capitis
Interventions
Drug: fluconazole
First Posted Date
2008-03-27
Last Posted Date
2021-07-16
Lead Sponsor
Pfizer
Target Recruit Count
185
Registration Number
NCT00645242
Locations
🇵🇷

Pfizer Investigational Site, Ponce, Puerto Rico

Single Dose Versus Two Weeks Course of Fluconazole in the Treatment of Oropharyngeal Candidiasis in HIV Infected Individuals in Tanzania

Phase 4
Completed
Conditions
Oropharyngeal Candidiasis
Interventions
Drug: fluconazole
First Posted Date
2007-11-04
Last Posted Date
2008-05-07
Lead Sponsor
Netherlands Organisation for Scientific Research
Target Recruit Count
220
Registration Number
NCT00553137
Locations
🇹🇿

ART clinic Muhimbili National Hospital/Muhimbili University College of Health Sciences, Dar es Salaam, Tanzania

Clinical Significance of Smear or Culture Positive for Candida Spp. From Sputum Three Times a Week

Phase 4
Conditions
Pulmonary Candidiasis
First Posted Date
2007-10-02
Last Posted Date
2010-12-14
Lead Sponsor
Capital Medical University
Target Recruit Count
200
Registration Number
NCT00537888
Locations
🇨🇳

Beijing Chaoyang Hospital,Affiliate of Capital Medical University, Beijing, Beijing, China

POS vs FLU for First Line Treatment of Coccidioidomycosis (Study P04558Am1)(COMPLETED)

Phase 3
Completed
Conditions
Coccidioidomycosis
Interventions
Drug: Fluconazole
Drug: Posaconazole
First Posted Date
2007-01-18
Last Posted Date
2017-04-11
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
16
Registration Number
NCT00423267

Diabetes Mellitus and Vulvovaginal Candidiasis

First Posted Date
2006-07-18
Last Posted Date
2008-05-22
Lead Sponsor
Indian Council of Medical Research
Target Recruit Count
100
Registration Number
NCT00353561
Locations
🇮🇳

Dr Ravinder Goswami, Delhi, India

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy